Biogen Inc. stock price, BIIB

Biogen Inc. stock chart:



Biogen Inc. close price: 272.94

Stock price forecast:

UP TO +0.22%
Target: 273.54

Total forecasts: 82
Reached: 47 (57.32%)

Total Win: 336.69 (121.44%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
90834857.83%339.061.47%9,634.71-81.81-0.85%257.251.11%
302300.00%0.000.00%6,249.4328.190.45%28.190.45%
141500.00%0.000.00%4,067.3426.760.66%26.760.66%
7800.00%0.000.00%2,179.254.270.20%4.270.20%

Showing 1-10 of 448 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-04-23272.94273.550000-00-00
2017-04-22272.94273.560000-00-00
2017-04-21272.46273.380000-00-00
2017-04-20271.94275.130000-00-00
2017-04-19271.16274.880000-00-00
2017-04-18274.05278.050000-00-00
2017-04-17271.88276.920000-00-00
2017-04-16271.88277.010000-00-00
2017-04-15271.88277.110000-00-00
2017-04-14271.88277.20000-00-00

Biogen Inc. latest news:


  • 03/31/2017 11:02:45

    Biogen wins Tecfidera U.S. patent dispute with Forward Pharma

    A U.S. patent board on Friday ruled against Danish drugmaker Forward Pharma A/S (FWP), finding Biogen's patents on its blockbuster multiple sclerosis drug Tecfidera to be valid. The ruling by the U.S. Patent Trial and Appeal Board frees Bigoen Inc from future royalty payments to Forward and sent the Danish firm's shares down nearly 20 percent.

  • 03/31/2017 10:27:14

    Biogen stock rises, Forward Pharma halted down 20% after patent ruling

    Shares of Biogen Inc. (BIIB) rose Friday, while Forward Pharma A/S (FWP) shares were halted after falling almost 20%, after Biogen was reported to have won a patent ruling. Patent Office ruled in favor of Biogen in a patent interference proceeding related to its multiple sclerosis drug Tecfidera, according to Evercore ISI analyst Umer Raffat. Biogen paid Forward Pharma (FWP) $1.25 billion in February related to the patent that covers ways of treating MS patients.

  • 03/21/2017 10:26:38

    Biogen wins ruling in Tecfidera IP case; shares rise

    Biogen Inc(BIIB) on Tuesday won an intellectual property rights ruling against hedge fund manager Kyle Bass over its top multiple sclerosis pill, Tecfidera, pushing shares up more than 1 percent on a day when most U.S. stocks were down. The ruling came from the U.S. Patent and Trademark Office's Patent Trial and Appeal Board in Washington.

  • More trends:

    Biolase, Inc.BIOL | BioLife Solutions, Inc.BLFS | BioLineRx Ltd.BLRX | BioMarin Pharmaceutical Inc.BMRN | BiondVax Pharmaceuticals Ltd.BVXV | BiondVax Pharmaceuticals Ltd.BVXVW | Bio-Path Holdings, Inc.BPTH | BioScrip, Inc.BIOS | BioShares Biotechnology Clinical Trials FundBBC | BioShares Biotechnology Products FundBBP |